Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ICU kidney patients: do blood thinners need a new recipe?

NCT ID NCT07384598

Knowledge-focused Sponsor: Clinique Saint Pierre Ottignies Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the blood thinner enoxaparin works in critically ill ICU patients with kidney failure, some on dialysis and some not. Researchers will measure drug levels in the blood over 24 hours after a daily shot. The goal is to see if current dosing is enough to prevent dangerous clots, since kidney problems can change how the drug is cleared from the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
enoxaparin (a blood thinner)
What this could lead to
If successful, this could lead to better dosing guidelines for blood thinners in ICU patients with kidney problems, reducing clot risks.
What could go wrong
This is a small, early-stage observational study (60 people) that only measures drug levels, not actual outcomes like clot prevention. Results may not apply to all ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 year old * Hospitalized in the ICU. * Equiped with an arterial line. * Indication for thromboprophylaxis with a daily prophylactic dose of enoxaparin. * Additionnally: * For cohort 1: severe renal failure (KDIGO stage ≥2) without CVVH AND SOFA score ≥4. * For cohort 2: severe renal failure (KDIGO stage ≥2) with CVVH AND sequential organ failure assessment (SOFA) score ≥4. * For cohort 3: no renal failure (creatinine clearance \> 60 ml/min) Exclusion Criteria: * Platelet count \< 50 000/μl. * CHILD PUGH stage C cirrhosis. * Known coagulation disorder. * Patient treated in the last 3 days with direct oral anticoagulants. * Patient treated in the last 24h with LMWH before enrollment. * High bleeding risk with contra indication for standard dose of LMWH prophylaxis, as per investigator judgment * Indication for therapeutic anticoagulation (including CVVH with systemic heparin anticoagulation). * Body weight \< 50 kg or \> 120 kg. * Evidence of recovery of renal function before enrollment, based on investigator judgement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute renal failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury Critical Illness kidney failure venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical illness Intensive care (ICU) Thromboprophylaxis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.